Compare Abbott Laboratories (ABT) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Under Armour Inc Class A — how do they compare? Abbott Laboratories trades at $109.48 (market cap $187.95B), while Under Armour Inc Class A trades at $5.38 (market cap $2.26B). The key difference: Abbott Laboratories is far larger — about 83.2× Under Armour Inc Class A's market cap, and Abbott Laboratories pays a 2.32% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| ABT | UAA | |
|---|---|---|
Market Cap | $187.95B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $8.14 |
52-Week Low | $82.57 | $4.17 |
Enterprise Value | $214.96B | $3.24B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Under Armour (UAA) trades at $5.86, down 4.09% today, reflecting ongoing challenges. The stock shows a bearish technical trend with support near $5.00. Fundamentally, the company reported a net loss of -$201.27M in 2025 with a negative net margin of -9.99%, though recent Q2 2026 earnings beat expectations. Revenue declined to $5.16B in 2025, and cash flow turned negative at -$361.87M. Analyst sentiment is mixed with a consensus price target of $6.67 but a majority hold rating.
The outlook remains cautious due to weak North American demand and margin pressures. Investment opportunities exist if the company executes its full-price strategy successfully, but risks include persistent revenue declines and high debt levels. The stock's proximity to its low price target of $5.00 underscores downside vulnerability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
